IL2 and systemic lupus erythematosus: IL-2-JES6-1A12 selectively expanded Tregs and improved symptoms in mouse models of asthma [125], experimental autoimmune encephalomyelitis (EAE [126];), transplantation [127], myasthenia gravis [128], and SLE [129].